Dr Rachel Midgley, MD PhD - University of Oxford - Doctor

Dr Rachel Midgley

MD PhD

University of Oxford

Doctor

Oxford, Oxfordshire | United Kingdom

Main Specialties: Oncology

Additional Specialties: Medical Oncology

Dr Rachel Midgley, MD PhD - University of Oxford - Doctor

Dr Rachel Midgley

MD PhD

Introduction

Primary Affiliation: University of Oxford - Oxford, Oxfordshire , United Kingdom

Specialties:

Additional Specialties:

Publications

33Publications

836Reads

16Profile Views

889PubMed Central Citations

'Toxgnostics': an unmet need in cancer medicine.

2014 Jun;14(6):440-5. doi: 10.1038/nrc3729. Epub 2014 May 15

Nat Rev Cancer

If we were to summarize the rationale that underpins medical oncology in a Latin aphorism, it might be 'veneno ergo sum'; that is, I poison, therefore I am. The burden of chemotherapy-associated toxicity is well recognized, but we have relatively few tools that increase the precision of anticancer drug prescribing. We propose a shift in emphasis from the focussed study of polymorphisms in drug metabolic pathways in small sets of patients to broader agnostic analyses to systematically correlate germline genetic variants with adverse events in large, well-defined cancer populations. Thus, we propose the new science of 'toxgnostics' (that is, the systematic, agnostic study of genetic predictors of toxicity from anticancer therapy).

View Article
May 2014
11 Reads

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

J Clin Oncol 2014 Apr 3;32(10):1031-9. Epub 2014 Mar 3.

Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Ian Tomlinson, Wellcome Trust Centre for Human Genetics, NIHR Comprehensive Biomedical Research Centre, University of Oxford; Dan Rosmarin, David Church, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Rachel Midgley, David Kerr, and George Nicholson, University of Oxford, Oxford; Michael Braun, The Christie NHS Foundation Trust, Manchester; Matthew Seymour, St James's University Hospital, Leeds; Lindsay Thompson, Medical Research Council Clinical Trials Unit; Rohini Sharma, Imperial College Healthcare NHS Trust, Hammersmith and Charing Cross Hospitals, London, United Kingdom; Anna Gonzalez-Neira, Spanish National Cancer Research Centre; Miguel Martin, Instituto de Investigacion Sanitaria Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid; Nuria Ribelles, Hospital Universitario Virgen de la Victoria, Málaga; Eva Martinez-Balibrea, Institut Català d'Oncologia, Institut de Recerca Sanitària Germans Trias i Pujol, Barcelona; Jesus Garcia-Foncillas, University Clinic of Navarra, University of Navarra, Pamplona, Spain; Daniel Sargent, Erin Green, Mayo Clinic, Rochester, MN; Howard McLeod, University of North Carolina, Chapel Hill, NC; Ulrich M. Zanger, Matthias Schwab, Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart; Ulrich M. Zanger, Matthias Schwab, University Hospital Tuebingenl, Tuebingen, Germany; Benjamin Lacas, Valérie Boige, Jean-Pierre Pignon, Institut Gustave Roussy, Villejuif; Marie-Christine Etienne-Grimaldi, Gérard Milano, Centre Antoine Lacassagne, Nice; Thierry Lecomte, Pierre Laurent-Puig, Assistance Publique Hopitaux de Paris, Hopital Européen Georges Pompidou, Paris; Alain Morel, Institut National de la Sante et de la Recherche Medicale U564, Centre Paul Papin, Angers, France; Shoaib Afzal, Henrik Enghusen, Laboratory of Clinical Pharmacology, Rigshospitalet, Copenhagen; Sør

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.1857DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879695PMC
April 2014
77 Reads
37 Citations
18.430 Impact Factor

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

J Clin Oncol 2013 Dec 23;31(34):4297-305. Epub 2013 Sep 23.

Enric Domingo, David N. Church, Rajarajan Ramamoorthy, and Ian P.M. Tomlinson, The Wellcome Trust Centre for Human Genetics, University of Oxford; David N. Church, David J. Kerr, and Rachel Midgley, Oxford Cancer Centre, Churchill Hospital; Yoko Yanagisawa, Elaine Johnstone, David J. Kerr, and Rachel Midgley, University of Oxford, Oxford; Rajarajan Ramamoorthy and Brian Davidson, University College London, Royal Free Hospital, London, United Kingdom; and Oliver Sieber, Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/09/18/JCO.2013.50
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.50.0322
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.50.0322DOI Listing
December 2013
49 Reads
53 Citations
18.430 Impact Factor

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Invest New Drugs 2013 Oct 28;31(5):1228-35. Epub 2013 Feb 28.

Department of Medical Oncology, University of Oxford Churchill Hospital, Oxford, OX3 7LJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9938-7DOI Listing
October 2013
20 Reads
1 Citation
2.920 Impact Factor

TGF-β: an emerging player in drug resistance.

Cell Cycle 2013 Sep 12;12(18):2960-8. Epub 2013 Aug 12.

Division of Molecular Carcinogenesis; The Netherlands Cancer Institute; Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.26034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875670PMC
September 2013
19 Reads
22 Citations

Biomarkers in early-stage colorectal cancer: ready for prime time?

Dig Dis 2012 23;30 Suppl 2:27-33. Epub 2012 Nov 23.

Oxford Cancer Centre, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000341890DOI Listing
June 2013
7 Reads
5 Citations
1.832 Impact Factor

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Invest New Drugs 2013 Apr 2;31(2):370-80. Epub 2012 Jun 2.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9825-7DOI Listing
April 2013
25 Reads
12 Citations
2.920 Impact Factor

Adjuvant chemotherapy for stage II colon cancer: less complicated than we thought.

J Clin Oncol 2013 Apr 18;31(12):1611. Epub 2013 Mar 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.2852DOI Listing
April 2013
12 Reads
18.430 Impact Factor

Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer.

J Hum Genet 2012 Nov 9;57(11):709-716. Epub 2012 Aug 9.

Department of Clinical Pharmacology, Cancer and Immunogenetics Laboratory, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/jhg201299
Publisher Site
http://dx.doi.org/10.1038/jhg.2012.99DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140019PMC
November 2012
15 Reads
4 Citations
2.462 Impact Factor

The emergence of 'omics for the management of colorectal cancer.

Curr Opin Oncol 2011 Jul;23(4):410-4

Department of Clinical Pharmacology, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328347ae49DOI Listing
July 2011
26 Reads
4.470 Impact Factor

Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients.

J Hum Genet 2011 Jan 25;56(1):58-63. Epub 2010 Nov 25.

Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jhg.2010.144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140020PMC
January 2011
17 Reads
4 Citations
2.462 Impact Factor

Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?

Nat Rev Clin Oncol 2010 Oct;7(10):556-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.140DOI Listing
October 2010
11 Reads
14.180 Impact Factor

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

J Clin Oncol 2010 Oct 13;28(30):4575-80. Epub 2010 Sep 13.

Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.29.6244DOI Listing
October 2010
39 Reads
24 Citations
18.430 Impact Factor

Gene profiling in early stage disease.

Cancer J 2010 May-Jun;16(3):210-3

Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3181e07606DOI Listing
September 2010
23 Reads
1 Citation
4.240 Impact Factor

Can we treat cancer for a dollar a day? Guidelines for low-income countries.

N Engl J Med 2010 Aug;363(9):801-3

Sidra Medical and Research Center, Doha, Qatar.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1002812DOI Listing
August 2010
10 Reads
13 Citations
55.873 Impact Factor

Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

J Clin Oncol 2010 Jul 24;28(20):3210-2. Epub 2010 May 24.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.28.9322DOI Listing
July 2010
11 Reads
10 Citations
18.430 Impact Factor

Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Sci Transl Med 2010 Jul;2(40):40ra50

Department of Medical Oncology, Churchill Hospital, Headington, Oxford OX3 7LJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3000615DOI Listing
July 2010
37 Reads
2 Citations
15.843 Impact Factor

Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver.

Semin Oncol 2010 Apr;37(2):149-59

Medical Oncology Unit, Churchill Hospital, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2010.03.005DOI Listing
April 2010
15 Reads
5 Citations
3.900 Impact Factor

Genetic prognostic and predictive markers in colorectal cancer.

Nat Rev Cancer 2009 Jul 18;9(7):489-99. Epub 2009 Jun 18.

Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2645DOI Listing
July 2009
32 Reads
195 Citations
37.400 Impact Factor

Evolution of nonsurgical therapy for colorectal cancer.

Nat Clin Pract Gastroenterol Hepatol 2009 Feb 20;6(2):108-20. Epub 2009 Jan 20.

Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road, Off Roosevelt Drive, Headington, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpgasthep1337DOI Listing
February 2009
13 Reads
7 Citations

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

Hepatology 2009 Jan;49(1):124-32

Cancer Research UK Clinical Trials Unit, CR UK Institute for Cancer Studies, Clinical Research Block.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.22626DOI Listing
January 2009
51 Reads
55 Citations
11.055 Impact Factor

Capecitabine: have we got the dose right?

Nat Clin Pract Oncol 2009 Jan 21;6(1):17-24. Epub 2008 Oct 21.

Department of Clinical Pharmacology, University of Oxford, Woodstock Road, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1240DOI Listing
January 2009
8 Reads
10 Citations

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

N Engl J Med 2007 Jul;357(4):360-9

Oncology Clinical Trials Office, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa071841DOI Listing
July 2007
53 Reads
33 Citations
55.873 Impact Factor

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

Nat Clin Pract Oncol 2005 Jul;2(7):364-9

Cancer Research UK Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK.

View Article

Download full-text PDF

Source
July 2005
4 Reads
13 Citations

Bevacizumab--current status and future directions.

Ann Oncol 2005 Jul 6;16(7):999-1004. Epub 2005 Jun 6.

Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdi208DOI Listing
July 2005
7 Reads
12 Citations
7.040 Impact Factor

Colorectal cancer.

Acta Oncol 2003 ;42(4):263-75

Department of Clinical Pharmacology, The University of Oxford, Radcliffe Infirmary, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02841860310000412DOI Listing
August 2003
3 Reads
5 Citations
3.000 Impact Factor

Immunotherapy for colorectal cancer.

Expert Rev Anticancer Ther 2003 Feb;3(1):63-78

Department of Health Clinician Scientist and Specialist Registrar (Medical Oncology), Cancer Research UK, Churchill Hospital, Oxford.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.3.1.63DOI Listing
February 2003
6 Reads
2 Citations
2.250 Impact Factor

Ras as a target in cancer therapy.

Crit Rev Oncol Hematol 2002 Nov;44(2):109-20

CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, Edgbaston, UK.

View Article

Download full-text PDF

Source
November 2002
4 Reads
4 Citations
4.030 Impact Factor